A Phase II, Open-label, Randomized Trial to Compare Anlotinib and Immunotherapy and Capecitabine Versus Investigator's Choice Therapy in High Risk ctDNA Positive, Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Latest Information Update: 01 Jun 2025
At a glance
- Drugs Benmelstobart (Primary) ; Capecitabine (Primary) ; Catequentinib (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Jun 2025 New trial record